Revenue
2018
2019
2020
2021
2022
2023
2024
2025
CAPRICOR THERAPEUTICS, INC. (CAPR)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $22.3M | $25.2M | $2.6M | $244,898 | $310,250 | $1.0M | $1.7M | $2.7M | $4.0M | $5.5M | $4.8M | $503,233 | $195,500 | $1.4M | — | — | — | — | — |
| Research & development | $84.5M | $50.0M | $36.4M | $21.8M | $13.6M | $8.5M | $5.1M | $12.1M | $10.8M | $16.0M | $13.8M | $7.8M | $5.2M | $2.6M | $4.1M | $4.1M | — | — | — | — |
| Operating expenses | $108.1M | $64.8M | $49.3M | $32.2M | $21.2M | $14.0M | $8.7M | $17.0M | $15.5M | $21.0M | $18.1M | $10.8M | $7.4M | $4.0M | $6.3M | $6.3M | — | — | — | — |
| Operating income | −$108.1M | −$42.6M | −$24.1M | −$29.7M | −$20.9M | −$13.7M | −$7.7M | −$15.3M | −$12.9M | −$17.0M | −$12.6M | −$6.0M | −$6.9M | −$2.1M | −$4.9M | −$6.3M | — | — | — | — |
| EBITDAderived | −$106.3M | −$41.1M | −$23.0M | −$29.2M | −$20.7M | −$13.5M | −$7.6M | −$15.2M | −$12.7M | −$16.9M | −$12.5M | −$6.0M | −$6.9M | −$2.1M | −$4.9M | −$6.3M | — | — | — | — |
| Net income | −$105.0M | −$40.5M | −$22.3M | −$29.0M | −$20.0M | −$13.7M | −$7.6M | −$15.2M | $2.4M | −$18.8M | −$12.9M | −$6.2M | −$8.9M | −$2.1M | −$1.1M | −$1.1M | −$148,970 | −$630,859 | −$979,076 | −$1.2M |
| Basic EPSper diluted share | -$2.26 | -$1.15 | -$0.83 | -$1.18 | -$0.87 | -$0.88 | -$2.06 | -$5.17 | $0.10 | -$1.01 | -$0.81 | -$0.53 | -$0.85 | -$0.21 | -$0.13 | -$0.19 | — | — | — | — |
| Diluted EPSper diluted share | -$2.26 | -$1.15 | -$0.83 | -$1.18 | -$0.87 | -$0.88 | -$2.06 | -$0.52 | $0.09 | -$1.01 | -$0.81 | -$0.53 | -$0.85 | -$0.21 | -$0.13 | -$0.19 | — | — | — | — |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 25, 2026Form 4 | Bergmann AnthonyCHIEF FINANCIAL OFFICER | SellCommon Stock | 24.1K | $30.38 | $732.2K | 11.2K |
| Jun 25, 2026Form 4 | Krasney KarenEVP, GENERAL COUNSEL | SellCommon Stock | 24.1K | $30.38 | $732.2K | 30.5K |
| Jun 24, 2026Form 4 | Bergmann AnthonyCHIEF FINANCIAL OFFICER | SellCommon Stock | 400 | $30.00 | $12.0K | 11.2K |
| Jun 24, 2026Form 4 | Krasney KarenEVP, GENERAL COUNSEL | SellCommon Stock | 400 | $30.00 | $12.0K | 30.5K |
| Jun 22, 2026Form 4 | Bergmann AnthonyCHIEF FINANCIAL OFFICER | SellCommon Stock | 500 | $30.00 | $15.0K | 11.2K |